A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/Ritonavir

Oral direct-acting antivirals (DAAs) are the main therapy for hepatitis C virus (HCV)-associated liver disease in Japan. Daclatasvir/asunaprevir is the first agent and sofosbuvir/ledipasvir is the secondary agent for HCV genotype 1b. More recently, ombitasvir/paritaprevir/ritonavir is also recommend...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Kazuo Tarao, Kouzo Yamada
Format: Artigo
Idioma:Inglês
Publicat: Karger Publishers 2017-06-01
Col·lecció:Case Reports in Gastroenterology
Matèries:
Interstitial pneumonia
Direct-acting antivirals
Dry cough
Hepatitis C virus liver disease
Ombitasvir/paritaprevir/ritonavir
Accés en línia:http://prod.karger.com/Article/FullText/462965
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars